# Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

> **NCT05749302** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 500 (estimated)

## Conditions studied

- Malignancy

## Interventions

- **DRUG:** Al18F-NOTA-FAPI

## Key facts

- **NCT ID:** NCT05749302
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-08
- **Primary completion:** 2025-03-08
- **Final completion:** 2026-01-08
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749302, "Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05749302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*